Intellia Therapeutics Inc NTLA
There have not been any declared dividends recently.
|Summary||Previous dividend||Next dividend|
Enter the number of Intellia Therapeutics Inc shares you hold and we'll calculate your dividend payments:
Sign up for Intellia Therapeutics Inc and we'll email you the dividend information when they declare.
Add Intellia Therapeutics Inc to receive free notifications when they declare their dividends.
Your account is set up to receive Intellia Therapeutics Inc notifications.
|Status||Type||Decl. date||Ex-div date||Pay date||Decl. Currency||Forecast amount||Decl. amount||Accuracy|
|There are no Intellia Therapeutics Inc dividends.|
|2022||Sign Up Required|
Intellia Therapeutics Inc Optimized Dividend Chart
About Intellia Therapeutics Inc
Intellia Therapeutics, Inc. is a clinical-stage genome editing company. The Company is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid (DNA). It is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. Its lead in vivo candidate, NTLA-2001, is for the treatment of transthyretin (ATTR) amyloidosis, as well as NTLA-2002 for the treatment of hereditary angioedema (HAE). The Company is developing ex vivo applications to address immuno-oncology and autoimmune diseases. Its advanced ex vivo programs include a wholly owned T cell receptor (TCR)-T cell candidate, NTLA-5001 for the treatment of acute myeloid leukemia (AML) and hematopoietic stem cells (HSCs) for the treatment of sickle cell disease.
- Pharmaceuticals & Biotechnology
- United States
- Share Price
- $46.94 (yesterday's closing price)
- Shares in Issue
- 76 million
- Market Cap
- Market Indices